The landscape of Parkinson’s Disease (PD) treatment is rapidly evolving, moving beyond symptom management towards potential disease modification and earlier intervention. As 2025 draws to a close, several clinical trials are poised to significantly impact how we understand and treat this neurodegenerative disorder. Here’s a look at the most promising developments and what they could mean for patients and neurologists alike.
The Quest for Disease Modification: LRRK2 Inhibition
One of the most closely watched trials is the LUMA study, investigating BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2). LRRK2 mutations are a known genetic risk factor for PD, making it a compelling therapeutic target. The trial, involving 650 participants across 113 sites, aims to determine if blocking LRRK2 can slow disease progression in early-stage PD. While a previous phase 3 trial (LIGHTHOUSE) was discontinued due to logistical complexities, the continued focus on BIIB122 signals confidence in the underlying science.
Pro Tip: LRRK2 inhibitors represent a paradigm shift in PD research. Historically, treatments have focused on dopamine replacement. Targeting the underlying genetic drivers of the disease offers the potential for a more lasting impact.
GBA-PD: A Personalized Approach to Treatment
Genetic factors play a crucial role in PD, and mutations in the GBA1 gene are increasingly recognized as a significant risk factor. The ACTIVATE trial is evaluating BIA 28-6156, a GCase enzyme-targeting therapy, specifically for patients with GBA-associated Parkinson’s Disease (GBA-PD). This represents a move towards personalized medicine, tailoring treatment to an individual’s genetic profile. Early data suggests BIA 28-6156 is well-tolerated, with manageable side effects like headache and fatigue.
Did you know? Approximately 5-10% of individuals with Parkinson’s Disease have a mutation in the GBA1 gene. These patients often experience a more rapid disease progression and earlier onset of motor symptoms.
Beyond Dopamine: Exploring Novel Targets
The search for effective PD treatments extends beyond dopamine-related pathways. A small but intriguing study is investigating the effects of lithium on brain biomarkers in early-stage PD. Lithium, traditionally used for bipolar disorder, has shown neuroprotective properties in preclinical studies. The trial will assess changes in MRI-derived free water levels and neurofilament light chain, potentially offering insights into disease modification.
This approach highlights the growing recognition that PD is a multifaceted disease, involving multiple biological pathways. Exploring drugs with diverse mechanisms of action could unlock new therapeutic avenues.
Gene Therapy: A Potential One-Time Treatment
AB-1005, an investigational gene therapy, is generating excitement in the PD community. The REGENERATE-PD trial is evaluating its efficacy in delivering glial cell line-derived neurotrophic factor (GDNF) directly to the brain. Previous phase 1b data showed promising putamen coverage and a favorable safety profile. Gene therapy offers the potential for a one-time treatment that could provide long-lasting benefits, reducing the burden of chronic medication.
Real-Life Example: Patients participating in the AB-1005 trial have reported improvements in motor symptoms and a reduction in medication requirements, although larger studies are needed to confirm these findings.
Improving Existing Therapies: Continuous Levodopa Infusion
While disease-modifying therapies are the ultimate goal, improving the delivery and efficacy of existing treatments remains crucial. The extension study of AbbVie’s foscarbidopa/foslevodopa (Vyalev) is evaluating the long-term safety and tolerability of this novel subcutaneous infusion. Vyalev provides continuous levodopa delivery, potentially reducing motor fluctuations and improving quality of life for patients with advanced PD.
The Role of Neuroinflammation: Citalopram as a Potential Protector
Emerging research suggests that neuroinflammation plays a significant role in the progression of Parkinson’s Disease. A proof-of-concept study is investigating whether citalopram, a commonly used antidepressant, can reduce amyloid-beta plaque buildup in the visuospatial cortex, a brain region affected in PD. This study explores a novel approach to potentially slow cognitive decline associated with the disease.
Looking Ahead: Key Trends in PD Research
Several key trends are shaping the future of PD research:
- Precision Medicine: Tailoring treatment based on individual genetic and biomarker profiles.
- Disease Modification: Focusing on therapies that slow or halt disease progression, rather than just managing symptoms.
- Biomarker Development: Identifying reliable biomarkers for early diagnosis and monitoring treatment response.
- Gene Therapy: Exploring the potential of gene therapy to deliver therapeutic genes directly to the brain.
- Neuroinflammation: Investigating the role of inflammation in disease progression and developing anti-inflammatory therapies.
FAQ
- What is LRRK2? LRRK2 is a kinase enzyme, and mutations in the gene that codes for it are a common genetic cause of Parkinson’s Disease.
- What is GBA-PD? GBA-PD refers to Parkinson’s Disease caused by a mutation in the GBA1 gene.
- Is gene therapy a cure for Parkinson’s Disease? Currently, gene therapy is not a cure, but it holds promise as a potential long-term treatment option.
- What are biomarkers? Biomarkers are measurable indicators of a disease state, used for diagnosis, monitoring, and treatment response.
Want to learn more? Explore our other articles on Parkinson’s Disease treatments and neurodegenerative disorders. Subscribe to our newsletter for the latest updates on PD research and clinical trials.
Worth a look